LUSC is associated with a poor clinical outcome, particularly in the absence of targeted agents, compared with lung adenocarcinoma.[2,3] Since the early 2000s, the development of molecular inhibitors targeting epidermal growth factor receptor, vascular endothelial growth factor, and anaplastic lymphoma kinase has significantly improved the prognosis of patients with lung adenocarcinoma. The gene discussed is ALK; the disease is lung adenocarcinoma.